The main country of operation and country of incorporation is the UK. Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody®, Moditope® and AvidiMab™ platforms. The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to reject or kill the growing tumour.

The information on this web site is being disclosed for the purposes of AIM Rule 26 and was last updated on 03 February 2020.